Burning Rock Biotech Limited (BNR), a leading provider of next-generation sequencing-based cancer diagnostics in China, demonstrates permissible core business activities in healthcare but fails key financial screening criteria due to exceptionally high debt and liquidity ratios relative to its low market capitalization. The company's operations across Central Laboratory, In-Hospital, and Pharma R&D segments align with Shariah principles promoting health preservation, with no non-compliant income sources identified. However, financial metrics indicate over-leveraging and excessive liquid assets, likely from conventional financing, leading to non-compliance across major standards. Index exclusion reinforces this assessment, though purification of 3.26% is required for minor interest income. Overall, BNR presents opportunities in ethical biotech but requires financial restructuring for Shariah suitability.